摘要
目的探讨通心络胶囊联合美托洛尔治疗冠心病稳定型心绞痛(SAP)的临床效果及安全性.方法选取本院2021年1-12月收治的冠心病SAP患者120例,按随机数字表法分为两组,每组60例.对照组口服美托洛尔治疗,观察组在此基础上加用通心络治疗,均持续用药12周.比较两组的临床疗效、血脂水平、心功能指标、心绞痛发作频率及不良反应发生情况.结果观察组的总有效率为95.00%,高于对照组的83.33%,差异有统计学意义(P<0.05).治疗后,观察组的三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平均低于对照组,高密度脂蛋白胆固醇水平高于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的左室射血分数高于对照组,左室收缩末内径、左室舒张末内径均短于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的心绞痛发作次数为(1.23±0.25)次/周,少于对照组的(1.89±0.34)次/周,单次持续时间为(2.14±0.38)min,短于对照组的(3.05±0.42)min,组间差异有统计学意义(P<0.05).两组均无严重不良反应.结论通心络胶囊联合美托洛尔可提高冠心病SAP的治疗效果,纠正患者脂代谢异常,减少心绞痛发作,减轻心功能损伤,安全可靠.
Objective To investigate the clinical efficacy and safety of Tongxinluo capsule combined with betaloc in the treatment of coronary heart disease with stable angina pectoris(SAP).Methods A total of 120 SAP patients with coronary heart disease admitted to our hospital from January to December 2021 were selected and were randomly divided into two groups,with 60 cases in each group.The control group was treated with betaloc orally,and the observation group was treated with Tongxinluo on this basis.Both groups were treated for 12 weeks.The clinical efficacy,blood lipid level,cardiac function index,angina pectoris attack frequency and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than 83.33%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of triglyceride,total cholesterol and low density lipoprotein cholesterol in the observation group were lower than those in the control group,while the levels of high density lipoprotein cholesterol were higher than those in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the left ventricular ejection fraction in the observation group was higher than that in the control group,while the left ventricular end-systolic diameter and left ventricular end-diastolic diameter were shorter than those in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the number of angina attacks in the observation group was(1.23±0.25)times/week,which was less than(1.89±0.34)times/week in the control group,and the single duration was(2.14±0.38)min,which was shorter than(3.05±0.42)min in the control group,and the differences between the groups were statistically significant(P<0.05).There were no serious adverse reactions in the two groups.Conclusion Tongxinluo capsule combined with metoprolol can improve the therapeutic effect of SAP in patients with coronary heart disease,correct the abnormal lipid metabolism,reduce the onset of angina pectoris,reduce the damage of heart function,which is safe and reliable.
作者
王继聪
邢瑞秀
WANG Jicong;XING Ruixiu(Clinical Pharmacy Office,Juxian People's Hospital,Rizhao Shandong,276500,China)
出处
《反射疗法与康复医学》
2022年第16期36-38,45,共4页
Reflexology And Rehabilitation Medicine
关键词
冠心病
稳定型心绞痛
通心络胶囊
美托洛尔
血脂水平
心功能
Coronary heart disease
Stable angina pectoris
Tongxinluo capsule
Betaloc
Blood lipid level
Cardiac function
作者简介
王继聪(1986-),男,山东日照人,本科,主管药师,研究方向:临床药学。
